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ABSTRACT 1 
Background: Evaluation of treatment options for localized prostate cancer continues to be 2 
among the highest priorities for comparative effectiveness research. Surgery and radiotherapy are 3 
the two most commonly used interventions. 4 
Objective: To provide a critical narrative review of the evidence surrounding the comparative 5 
effectiveness and harms of surgery and radiotherapy in the treatment of localized prostate cancer. 6 
Evidence acquisition: A collaborative critical narrative review of the literature was conducted. 7 
Evidence synthesis: Evidence to clearly guide treatment choice in prostate cancer remains 8 
insufficient. Randomized trials are underpowered for clinically-meaningful endpoints and have 9 
demonstrated no difference in overall or prostate cancer-specific survival. Observational studies 10 
have consistently demonstrated an absolute survival benefit for men treated with radical 11 
prostatectomy, but are limited by selection bias and residual confounding errors. Surgery and 12 
radiotherapy are associated with comparable health-related quality of life following treatment in 13 
three randomized trials. Randomized data regarding urinary, erectile, and bowel function show 14 
few long-term (>5 year) differences though short term continence and erectile function were 15 
worse following surgery and short term urinary bother and bowel function were worse following 16 
radiotherapy. There has been recent recognition of other complications which may significantly 17 
affect the life trajectory of those undergoing prostate cancer treatment. Of these, hospitalizations, 18 
the need for urologic, recto-anal and other major surgical procedures, and secondary cancers are 19 
more common among men treated with radiotherapy. Androgen deprivation therapy, frequently 20 
co-administered with radiotherapy, may additionally contribute to treatment-related morbidity. 21 
Technological innovation in surgery and radiotherapy have shown inconsistent oncologic and 22 
functional benefits.  23 
Conclusions: Due to underpowered randomized control studies and the selection biases inherent 24 
from observational studies, the question of which treatment provides better cancer control cannot 25 
be definitively answered now or in the near future. Complications following prostate cancer 26 
treatment are relatively common regardless of treatment approach. These include the commonly 27 
identified issues of urinary incontinence and erectile dysfunction and others including 28 
hospitalizations and invasive procedures to manage complications, and secondary malignancies. 29 
Whole population-based outcome studies, rather than clinical trial data, will be necessary to 30 
enable comprehensive understanding of the relative benefits and risks of each therapeutic 31 
approach. 32 
Patient summary: Surgery and radiotherapy are the most common interventions for men 33 
diagnosed with prostate cancer. Comparisons of survival after these treatments are limited by 34 
various flaws in the relevant studies. Complications are common regardless of treatment 35 
approach. 36 
 37 
 38 
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1. INTRODUCTION 1 
 For three decades, management options for patients with clinically-localized prostate 2 
cancer (PCa) have remained the same ± surgery, radiotherapy, and observation. Many men, 3 
particularly those who are older or have low-risk PCa, will not benefit from active 4 
intervention[1]. For men with a long life expectancy (>10 years), treatment is recommended for 5 
those with intermediate or high-risk PCa[2]. Both surgery and radiotherapy (now usually in 6 
combination with androgen deprivation therapy, ADT) have been used in the treatment of PCa 7 
for over 100 years. While other treatments such as high intensity frequency ultrasound (HIFU) 8 
and cryotherapy are gaining prominence, the volume of evidence surrounding intermediate- and 9 
long-term outcomes remains insufficient to guide treatment decision-making. Accordingly, these 10 
treatments are not routinely recommended in clinical practice guidelines[2].  11 
Without significant supportive evidence, surgery and radiotherapy (generally in 12 
combination with ADT) have been advocated as having similar oncologic efficacy. Thus, 13 
treatment counselling and decision making has been complex and predominately centred on risks 14 
of urinary incontinence and erectile dysfunction and other radiation-specific side-effects (and 15 
increasingly side effects of ADT as we have become aware of them in the past decade). The 16 
importance of localized PCa management is highlighted by its selection by the Institute of 17 
Medicine as one of the top 25 priorities for comparative effectiveness research[3]. In the past few 18 
years, a significant body of literature has emerged assessing survival and complications 19 
following treatment of localized PCa. Thus, in this collaborative narrative review, we summarize 20 
historical and contemporary data evaluating survival outcomes and complications following 21 
radical prostatectomy and radiotherapy in the treatment of clinically-localized PCa, including 22 
consideration for the role and toxicity of ADT co-administered in most modern radiotherapy 23 
regimes.  24 
 4 
 
2. EVIDENCE ACQUISITION 1 
 MEDLINE was systematically searched from inception until December 2016 using the 2 
IROORZLQJWHUPV³UDGLFDOSURVWDWHFWRP\´³UDGLRWKHUDS\´³EUDFK\WKHUDS\´³VXUYLYDO´3 
³FRPSOLFDWLRQV´DQG³RXWFRPHV´DORQJZLWKfree-text, related, derivative, and exploded terms. 4 
The lead author compiled a proposed bibliography and manuscript framework which was 5 
iteratively revised by all co-authors. Following agreement on manuscript structure, the first and 6 
senior authors drafted this narrative review that was critically revised by co-authors. The final 7 
manuscript represents the consensus of the authors. 8 
 9 
3. EVIDENCE SYNTHESIS 10 
 11 
3.1 Oncologic outcomes in prostate cancer research 12 
 Many cancer-related outcomes have been used in comparative effectiveness studies of 13 
PCa treatments including biochemical recurrence, clinical recurrence, metastasis, PCa-specific 14 
mortality and overall mortality. All-cause (overall) mortality is the most reliable endpoint of any 15 
oncology study and, according to the United States Food and Drug Administration, is the 16 
preferred endpoint due to its precision and lack of ascertainment bias[4]. Previous work has 17 
shown that PCa may be reliably ascertained as a cause of death from administrative records[5]. 18 
Thus, PCa-specific survival is an alternative outcome that may more directly assess the 19 
oncologic efficacy of PCa therapies.  20 
Biochemical recurrence (BCR) is the most commonly used outcome in PCa treatment 21 
efficacy studies as it develops relatively early following treatment[6]. While BCR is an important 22 
clinical event, most notably as it triggers further therapy with significant costs and quality of life 23 
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detriments[7-9], it is limited as a meaningful research outcome. First, approximately 10%  of 1 
men with BCR will develop clinical progression[10], and less than 5% at 5 years  will ultimately 2 
die of disease[10]. Thus, BCR is a poor surrogate measure for survival. Second, there exist 3 
innumerable definitions of biochemical recurrence (BCR). A systematic review of the literature 4 
in 2007 identified 53 different definitions for BCR following radical prostatectomy and 99 5 
different definitions for BCR following radiotherapy[11], making it difficult to compare 6 
outcomes between studies. Finally, given the intrinsically different definitions of BCR for 7 
patients treated initially with surgery and radiotherapy, the use of BCR to compare outcomes 8 
following treatment with the two modalities is inherently problematic. Both the Phoenix criterion 9 
and ASTRO criteria as a definition of BCR systematically overestimate biochemical-recurrence 10 
free survival for patients following radical prostatectomy[12]. Further, Lee et al. showed that 11 
among men with comparable five-year risks of BCR, those treated with radiotherapy as 12 
compared to surgery had significantly increased risk of PCa-specific mortality[13]. Thus, while 13 
clinically meaningful, BCR should not be used to compare oncologic efficacy of PCa treatments 14 
and this review focuses on survival outcomes.  15 
 16 
3.1.1 Randomized survival data 17 
Radical prostatectomy is the only treatment shown in a randomized controlled trial to 18 
improve overall and cancer-specific survival for patients with localized PCa, compared to 19 
watchful waiting[14]. In the Scandinavian Prostate Cancer Group Trial #4 (SPCG-4), Bill-20 
Axelson et al. randomized 695 men with early clinically-detected PCa to radical prostatectomy 21 
or watchful waiting[14]. In addition to a survival benefit, surgery reduced the risk of 22 
metastasis[14]. These benefits were not confirmed in a similar study (Prostate Cancer 23 
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Intervention versus Observation Trial, PIVOT)[15], though this study is limited by inclusion of 1 
proportionally more men with low-risk disease and more men with significant comorbidities and 2 
shorter follow-up (median 10 years). In the SPCG-4 trial, the benefit of surgery has continued to 3 
increase as ongoing follow-up has accrued.  4 
 Two older randomized trials compared survival outcomes following radical 5 
prostatectomy and radiotherapy. The first was conducted by the Uro-Oncology research group in 6 
the pre-PSA era[16] and the second by the Japanese Study Group for Locally Advanced Prostate 7 
Cancer more recently16. Both demonstrated improved outcomes in surgically treated patients, 8 
however due to methodologic limitations (including insufficient follow-up) and the evolution of 9 
medical practice (including stage migration due to the introduction of PSA screening), neither of 10 
these studies have influenced current clinical practice.  11 
Recently, the Prostate testing for cancer and Treatment (ProtecT) trial reported survival 12 
outcomes among 1643 patients randomized to active monitoring, radical prostatectomy and 13 
radiotherapy[17]. The investigators found no significant difference in their primary outcome of 14 
PCa specific mortality (p=0.48) with eight attributable deaths in the monitoring group, five in the 15 
surgery group and four in the radiotherapy group[17]. Overall mortality rates were also 16 
comparable (p=0.87). Limitations of applying these data to clinical practice have previously been 17 
reported[18,19]. Most notably, there is a lack of statistical power, a fact recognized years before 18 
manuscript publication[20], due to a significant overestimation of predicted mortality rates at the 19 
time of study design. In addition, there is over-representation of patients with low-risk disease 20 
among the study cohort[20]. Based on these limitations, it is unlikely that meaningful 21 
comparisons of mortality for patients treated with surgery and radiotherapy will ever be made 22 
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from this cohort. Nonetheless, ProtecT identified a significant reduction in both clinical 1 
progression and metastatic disease among men receiving definitive therapy.  2 
Among 89 patients with localized or locally-advanced PCa randomized to surgery or 3 
radiotherapy (EBRT + brachytherapy boost + ADT), Lennernas et al. recently reported no 4 
difference in overall or cancer specific mortality, though the authors correctly concluded that 5 
they were underpowered to assess survival outcomes[21]. 6 
 7 
3.1.2 Observational survival data 8 
Considering the limitations among available randomized trials, a recent meta-analysis of 9 
observational studies compared overall and prostate-cancer specific mortality for patients treated 10 
with surgery and radiotherapy[22]. Utilizing pooled results of 95,791 patients for the outcome of 11 
overall mortality and 118,830 patients for PCa-specific mortality, patients treated with 12 
radiotherapy had a significantly increased risk of death (overall mortality: HR 1.63, 95% CI 1.54 13 
± 1.73; PCa-specific mortality: HR 2.08, 95% CI 1.76 ± 2.47). These findings were robust to 14 
subgroup and sensitivity analyses including PCa risk categorization, study accrual period, 15 
radiotherapy modality (EBRT or brachytherapy), duration of follow-up, and geographic region 16 
of study[22]. It is notable that a survival benefit was found even among patients with low-risk 17 
disease, likely reflecting a combination of the Will Rogers phenomenon[23] and residual 18 
confounding. 19 
While observational data cannot account for unmeasured confounding in the manner of a 20 
randomized controlled trial, as others have highlighted[24,25], the included studies were deemed 21 
at low to moderate risk of bias using the Newcastle-Ottawa Scale, a validated measure 22 
recommended by the Cochrane Collaborative to evaluate observational studies[26]. In contrast, 23 
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another meta-analysis which downplayed differences in survival between surgery and 1 
radiotherapy[25] did not use a validated measure for bias assessment. Initially, the authors 2 
attempted to employ the GRADE criteria[27]. Rather than relying on this validated measure, 3 
they subsequently constructed a subjective UHOLDELOLW\VFDOHEDVHGRQWKHLU³SHUFHSWLRQVDERXWWKH4 
UHODWLYHLPSRUWDQFHRIHDFKIDFWRU´[25]. The authors deemed single institutional studies to be of 5 
KLJKHU³UHOLDELOLW\´Whan multi-institutional reports and penalized studies reporting on populations 6 
greater than 12,000 patients, even though these studies have greater external validity. Despite 7 
this, the authors demonstrated that radical prostatectomy was associated with improved overall 8 
and cancer-specific survival compared to radiotherapy.  9 
There are many ways to account for selection biases, most principally confounding by 10 
indication, in observational studies including regression techniques, propensity-score approaches 11 
(including matching and weighting), and instrumental variable techniques. Many of the studies in 12 
the meta-analysis included all identifiably relevant patient and tumor characteristics in regression 13 
or propensity-score matched analyses[22]. While these approaches account for observed 14 
confounders, instrumental variable analyses may also account for unmeasured confounding. 15 
Using such an approach in patients with ten-year predicted life expectancy, Sun et al. found 16 
improved survival among those treated with surgery compared to radiotherapy (HR 0.66, 95% CI 17 
0.56 ± 0.79)[28]. While instrumental variable analyses have been shown to provide less biases 18 
estimates of treatment effect[29], these techniques are unable to fully account for selection bias 19 
and consequently residual confounding remains[30]. Furthermore, there remain important 20 
statistical limitations with respect to their ability to determine differences in outcomes. To 21 
address such residual confounding, Cooperberg et al. performed an elegant sensitivity analysis in 22 
which Kattan scores were artificially increased for patients undergoing prostatectomy[31]. To 23 
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show that surgery was not better than radiation, there had to be an increase of more than 30 1 
Kattan points which was considered unrealistic.  2 
Other concerns with the meta-analysis of observational studies[22] include the relevance 3 
of the included treatments, given recent advances in radiotherapy. However, examining patients 4 
treated with dose-escalated IMRT (>81 Gy) compared to radical prostatectomy, Zelefsky et al. 5 
found comparable results[32]. Among patients with high grade PCa, Kishan et al. found no 6 
difference in overall survival between those treated surgically, those treated with EBRT and 7 
ADT, and those treated with EBRT, brachytherapy boost, and ADT[33]. While the authors found 8 
lower rates of metastasis among men receiving radiotherapy and ADT, this is confounded by 9 
short follow-up (<5 years) and the co-administration of ADT. 10 
 This meta-analysis represents Level 2a evidence, although the limitations to account for 11 
unmeasured confounding continue to be a problem for these studies [34]. Thus, despite a number 12 
of studies on this topic (Table 1), this remains an unresolved question.  13 
 14 
3.2 Global health-related quality of life 15 
 A recent systematic review highlighted the importance of patient-derived health related 16 
quality of life assessment in the evaluation of treatment outcomes in patients with urologic 17 
cancers[35]. While specific patient-reported functional domains are of interest and more likely to 18 
reflect treatment-related mechanisms, global health-related quality of life (HRQoL) may be more 19 
meaningful, despite limitations due to the ceiling effect of these instruments. Three 20 
contemporary randomized controlled trials assessed patient-reported outcomes (PROs) including 21 
global HRQoL (Table 2). Among the ProtecT cohort, Donovan et al. demonstrated no 22 
differences in physical health, mental health, anxiety or depression among men treated with 23 
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surgery or radiotherapy[36]. Lennernas et al. and Gilberti et al. similarly found no difference in 1 
overall measures of health-related quality of life whether patients were treated with EBRT or 2 
brachytherapy, as compared to radical prostatectomy[21,37]. PCa treatment may also affect the 3 
qualiW\RIOLIHRISDWLHQWV¶VSRXVHV[38]. Further work, including the development of measures 4 
which overcome the ceiling effect, is urgently needed in this area.  5 
 6 
3.3 )XQFWLRQDORXWFRPHV³FODVVLFFRPSOLFDWLRQV´ 7 
 The best characterized and most frequently discussed complications of PCa treatment are 8 
urinary incontinence and erectile dysfunction. SPCG-4 demonstrated that radical prostatectomy 9 
increased rates of each of these complications, while decreasing rates of urinary obstruction, 10 
compared to watchful waiting[39]. Due to field effects of radiotherapy, both EBRT and 11 
brachytherapy significantly affect the bowel and rectal domains of HRQoL[40]. While most 12 
bowel effects are transient, a proportion persist for many years after treatment[40]. Typically, 13 
bowel symptoms are worse for patients undergoing EBRT than those receiving 14 
brachytherapy[41]. 15 
As with global HRQoL, three randomized controlled trials compare patient-reported 16 
functional outcomes for those treated with surgery and radiotherapy. In the ProtecT study, 17 
surgery was associated with increased rates of urinary incontinence and erectile dysfunction 18 
while radiotherapy had greater obstructive urinary symptoms and bowel symptoms[36]. 19 
Differences in urinary incontinence and erectile dysfunction between treatment modalities 20 
diminished with longer follow-up[36], in keeping with the observational findings of the Prostate 21 
Cancer Outcomes Study[42]. Lennernas et al. found no significant differences in urinary 22 
urgency, urinary incontinence, erectile dysfunction, sexual interest, or rectal bleeding between 23 
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men treated with surgery or radiotherapy[21]. They noted significant worsening in urinary 1 
incontinence, erectile dysfunction, and sexual interest over time in both groups. Gilberti et al. 2 
found that men treated with brachytherapy had worse urinary function at six and 12 months, 3 
worse bowel function at 6 months and better erectile function at six months compared to those 4 
treated surgically[37]. However, there were no significant differences in any functional outcome 5 
at five years. 6 
 There is a wealth of observational data examining patient-reported functional outcomes. 7 
Most notably, the Prostate Cancer Outcomes Study recruited 3533 men from six SEER 8 
registries[42] where 1655 patients with localized disease received surgery or radiotherapy 9 
treatment within 1 year of diagnosis and completed follow-up surveys beyond two years. At two 10 
and five years following treatment, men receiving surgery were more likely to report urinary 11 
incontinence and erectile dysfunction while those receiving radiotherapy were more likely to 12 
report bowel urgency and bother due to bowel symptoms[42]. By 15 years, all differences 13 
became non-significant, except for bowel symptoms which remained higher in men treated with 14 
radiotherapy[42]. Also, by 15 years, most men had developed erectile dysfunction[42]. More 15 
recent observational data have corroborated these findings among men treated with modern 16 
treatments, albeit with short (two and three year) follow-up[43,44].  17 
Despite these data, a recent systematic review concluded there was insufficient data on 18 
symptomatic and quality-of-life outcomes following localized PCa treatment to provide 19 
meaningful treatment guidance[45]. In part, this is due to use of differing assessment measures. 20 
A recent Delphi consensus among patients, urologists and radiation oncologists sought to 21 
standardize the reporting of outcomes following localized PCa treatment[46]. They advocated 22 
using the Expanded Prostate Cancer Index Composite (EPIC-26) for assessment of patient-23 
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reported outcomes, though numerous others were also endorsed. Data collection for ten years 1 
following treatment was recommended. 2 
  3 
3.4 Functional outcomes: Novel complications 4 
 Complications related to PCa treatment may necessitate interventions including urologic 5 
procedures, rectal-anal procedures, and major surgery. These complications, including 6 
genitourinary or gastrointestinal bleeding, infection, and urinary obstruction, may also require 7 
planned or unplanned hospitalization[47]. Additionally, a further risk following radiotherapy is 8 
treatment-induced secondary malignancy.  9 
In a large, population-based cohort of patients treated for non-metastatic PCa in Ontario, 10 
Canada, radiotherapy treatment was associated with an increased risk of hospitalization, rectal-11 
anal procedures, major surgeries, and secondary cancers but lower risk of minimally-invasive 12 
urologic procedures, compared to surgery[47]. After propensity-score matching to account for 13 
baseline differences, patients receiving radiotherapy had increased long-term risk of all of these 14 
outcomes[48]. Validation in an independent cohort of patients from the United States showed 15 
that these complications frequently recur (mean 2.6 per patient) and continue for years following 16 
treatment[49,50]. Utilizing the same patient cohort but differing analytic methods, Williams et al. 17 
found no difference in treatment-related hospitalizations, though there was greater cost 18 
associated with treatment of patients who received radiotherapy[51].  19 
While the use of post-operative radiotherapy contributed to increased complication rates, 20 
when taken on an intention-to-treat basis, the initial decision to begin therapy with surgery was 21 
associated with lower long-term risk of all procedural interventions and hospitalizations[9].  22 
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Complications arising from radiotherapy, the end result of which is chronic tissue 1 
ischaemia[52], have a profoundly different prognosis than those arising following surgery, which 2 
maintains the underlying tissue integrity. Radiotherapy-association complications are 3 
significantly more burdensome and often entail a much slower recovery, with impaired long-4 
term function[53]. Most notably, urinary fistulae following prostate radiotherapy often require 5 
urinary diversion and are associated with significant morbidity[54]. 6 
In the Ontario cohort, patients treated with radiotherapy had a significantly increased risk 7 
of secondary cancers (standardized incidence rate (SIR) 2.0, 95% CI 1.7-2.3), driven by an 8 
excess of secondary cancers in men aged 40-65 at the time of radiotherapy (SIR 3.5, 95% CI 2.3-9 
4.7)[47]. This finding has recently been supported by a meta-analysis comprising 21 studies and 10 
up to 555,873 patients[55] which found an increased risk of in-field secondary malignancies 11 
(bladder, rectal and colorectal cancers) but not of out-of-field malignancies among patients 12 
treated with radiotherapy, though the absolute risk was small (0-1.4 cases per 100 patients 13 
treated)[55].  14 
 Finally, there is growing evidence that radiotherapy may exert systemic effects. That 15 
radiotherapy has effects beyond the treatment field is relatively well-established[56]. A 16 
combination of systemic effects and local toxicity to the femur and pelvis may explain an 17 
observed association between radiotherapy and fracture risk which has been demonstrated 18 
among women with pelvic malignancies[57,58]. There is recent evidence demonstrating an 19 
independent association between radiotherapy and fracture risk in men treated for PCa[59], 20 
though others have not demonstrated this relationship[60]. Additionally, we recently observed an 21 
independent association between radiotherapy for clinically-localized PCa and the development 22 
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of coronary artery disease, myocardial infarction, and sudden cardiac death[59], although this 1 
requires further validation. 2 
 3 
3.5 Effect of Androgen Deprivation Therapy 4 
 Androgen deprivation therapy (ADT) is often co-administered with radiotherapy based 5 
on evidence that it improves overall survival[61-63]. Thus, most radiation administered is in fact 6 
combination therapy. Long-term ADT (2 or 3 years) is recommended for patients with locally 7 
advanced disease rather than short-term therapy (6 months)[64]. However, among patients with 8 
localized disease, short-term ADT appears sufficient[65]. Nonetheless, both the ProtecT study 9 
and Lennernas et al. treated all patients receiving radiotherapy with ADT. 10 
 ADT is associated with detriments in bone health, cardiovascular disease, diabetes, 11 
sexual function, mental health, and cognition[66]. Further, ADT causes sexual dysfunction in 12 
more than 90% of treated men through decreased sexual interest (libido) and erectile 13 
function[67]. ADT has also been associated with decreases in penile length[68] and testicular 14 
size[69] which may be psychologically distressing and associated with treatment regret. A year 15 
following treatment, ADT was associated with significant impairments in HRQoL and with 16 
greater psychological distress than conservative management, while no differences were found 17 
between either surgery or radiotherapy and conservative management[70]. 18 
 Most studies assessing ADT toxicity were conducted among men with advanced or 19 
metastatic disease and without consideration for local treatment. Recently, the adverse 20 
cardiovascular and skeletal-related effects of ADT have been demonstrated among patients with 21 
localized disease, undergoing definitive local treatment in an observational cohort[59]. Among 22 
patients with intermediate- and high-risk clinically-localized PCa in the DART 01/05 23 
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randomized trial, longer durations of ADT (24 months) were associated with an increased risk of 1 
cardiovascular events, compared to short durations (4 months)[71]. However, comparing 2 
treatment with ADT to no ADT, a recent meta-analysis of randomized trials showed no increased 3 
risk of cardiovascular death[72]. Adjuvant ADT may potentiate the bowel and sexual toxicity of 4 
radiotherapy (either EBRT or brachytherapy)[40,73] and the urinary and sexual toxicity 5 
following radical prostatectomy[74]. Further, adjuvant ADT has been associated with significant 6 
impairments in HRQoL[40]. Among patients undergoing radiotherapy, neoadjuvant ADT 7 
resulted in significant impairment in sexual- and vitality-related quality of life within 2 months 8 
of initiating ADT[75]. 9 
 10 
3.6 Evolving treatment modalities 11 
 12 
3.6.1 Changes in surgical approach 13 
 Most survival and oncologic data for surgically treated patients presented in this 14 
manuscript are derived from patients treated with open retropubic radical prostatectomy. To our 15 
knowledge, there exists only one trial which randomized patients to open or robotic radical 16 
prostatectomy[76]. To date, only early perioperative outcomes are available. When assessed at 6 17 
and 12 weeks following surgery, there were no significant differences in urinary or sexual 18 
function. Conclusions regarding positive margin rates could not be made. 19 
 Several population-based, observational cohort studies have compared open and robotic 20 
approaches. Assessing oncologic outcomes, robotic prostatectomy has been associated with a 21 
lower risk of positive surgical margins and of requiring additional cancer therapies[77,78] but no 22 
difference in overall or PCa-specific mortality[79]. Functionally, using patient-reported outcome 23 
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PHDVXUHV2¶1HLOHWDOIRXQGWKDWSDWLHQWVWUHDWHGURERWLFDOO\KDGEHWWHUXULQDU\DQGVH[XDO1 
function six months postoperatively, compared with those treated with open surgery[80]. The 2 
difference in sexual function persisted while differences in urinary function disappeared by 12 3 
months. In contrast, Barry et al. found no difference in continence or sexual function based on 4 
operative technique[81]. 5 
Due to a combination of pro-innovation bias and changes in surgical training, it is likely 6 
that robotic prostatectomy will remain the preferred surgical approach. Centralization of care 7 
may lead to improved outcomes due to the established association between surgical volume and 8 
outcomes[82-84]. Further, operative advancements, including the use of a modified nerve-9 
sparing technique[85] and neurovascular structure-adjacent frozen-section examination[86], may 10 
contribute. 11 
 12 
3.6.2 Changes in radiotherapy delivery 13 
 Over the past two decades, intensity-modulated radiotherapy (IMRT) has largely 14 
supplanted 3-dimensional conformal radiotherapy (3D-CRT) for EBRT[87], and has been 15 
associated with less gastrointestinal toxicity, but comparable genitourinary toxicity[88,89]. 16 
Accompanying the transition to IMRT has been a trend towards dose-escalation, which has been 17 
shown to improve biochemical control and to reduce metastases in some randomized 18 
trials[90,91] although mortality appears comparable[88,92,93]. Early reports indicated that dose-19 
escalation may be associated with increased gastrointestinal toxicity[92,94]; however, a recent 20 
review concluded that toxicity profiles were likely similar between dose-escalated and non-dose-21 
escalated therapy[88]. Hypofractionation is associated with similar oncologic outcomes and 22 
toxicity, compared to conventional regimes[88,95,96]. Stereotactic body radiotherapy (SBRT) 23 
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combines dose-escalation and hypofractionation. While randomized comparisons to IMRT are 1 
ongoing, observational data suggest that SBRT has similar oncologic outcomes to IMRT[97] 2 
though SBRT but may be associated with increased erectile dysfunction[98], short-term 3 
genitourinary and gastrointestinal toxicity[99], and long-term genitourinary toxicity[99]. Finally, 4 
there has been interest in the use of proton EBRT though there is little evidence of improved 5 
oncologic or functional outcomes[100]. 6 
 In addition to the described advances in the delivery of EBRT, there has been significant 7 
scientific interest in brachytherapy despite persistent and ongoing declines in its utilization[101-8 
103]. The recently reported ASCENDE-RT trial demonstrated that the addition of brachytherapy 9 
boost to EBRT and ADT in men with intermediate- and high-risk disease was associated with 10 
improved biochemical control and comparable overall survival[104]. Brachytherapy boost was 11 
associated with increased genitourinary toxicity[105] and patient-reported worse overall health, 12 
sexual function, and urinary function[106].  13 
 14 
 15 
 16 
4. CONCLUSIONS 17 
Randomized trials assessing survival following surgery or radiotherapy in the treatment 18 
of clinically-localized PCa are significantly underpowered to address the question of relative 19 
superiority of surgery versus radiotherapy (and ADT) and are therefore limited in meaningfully 20 
informing clinical practice. Observational studies of hundreds of thousands of patients treated in 21 
clinical practice do not support oncologic equivalence of the two modalities, though this 22 
evidence is limited by selection bias. Complications following PCa treatment are relatively 23 
 18 
 
common. These include the commonly identified issues of urinary incontinence and erectile 1 
dysfunction but also others including hospitalizations and invasive procedures to manage 2 
complications, and secondary malignancies (Table 3). Thus, well powered and designed 3 
randomized controlled trials continue to be needed in order to assess the true effectiveness of 4 
these treatments to provide the definitive answer enabling enhanced patient and clinician 5 
decision-making when active treatment of localized PCa is to be undertaken. 6 
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Table 1. Key studies examining oncological outcomes of treatment of localized prostate cancer with radiotherapy and radical 
prostatectomy. 
Study identifier Design Exposures Sample size Findings Limitations 
Hamdy et al. Randomized 
controlled trial 
Radical prostatectomy 
vs. EBRT + ADT 
1098 No difference in PCSM 
(p=0.48) or OM (p=0.87) 
-Underpowered 
-Over-representation 
of low risk patients 
Lennernas et al. Randomized 
controlled trial 
Radical prostatectomy 
vs. EBRT + brachy 
boost + ADT 
89 No difference in PCSM -Underpowered 
Wallis et al. Meta-analysis of 
observational 
studies 
Radical prostatectomy 
vs. radiotherapy (EBRT 
or brachy) 
95,791 Increased OM and PCSM 
among patients treated 
with radiotherapy 
-Residual 
confounding 
Notes: EBRT = external beam radiotherapy; brachy = brachytherapy; ADT = androgen deprivation therapy; PCSM = prostate 
cancer specific mortality; OM = overall mortality. 
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Table 2. Key studies examining functional outcomes of treatment of localized prostate cancer with radiotherapy and radical 
prostatectomy. 
Study identifier Hamdy et al. Lennernas et al. Gilberti et al. Resnick et al. 
Study design Randomized 
controlled trial 
Randomized 
controlled trial 
Randomized controlled 
trial 
Observational cohort study 
Exposures Radical prostatectomy 
vs. EBRT + ADT 
Radical prostatectomy 
vs. EBRT + brachy 
boost + ADT 
Radical prostatectomy vs. 
brachytherapy 
Radical prostatectomy vs. 
EBRT 
Sample size 1098 89 174 1655 
Findings     
 Global HRQoL Equivalent Equivalent Equivalent - 
 Incontinence Greater in RP than RT Equivalent Equivalent Greater in RP (at 2/5 yrs) 
Equivalent (at 15 yrs) 
 Erectile 
dysfunction 
Greater in RP than RT Equivalent Greater in RP (short-term) 
Equivalent (long-term) 
Greater in RP (at 2/5 yrs) 
Equivalent (at 15 yrs) 
 Bowel 
symptoms 
Greater in RT than RP Equivalent Greater in RT (short-term) 
Equivalent (long-term) 
Greater in RT (at 2/5 yrs) 
Equivalent (at 15 yrs) 
 Obstructive 
urinary 
symptoms 
Greater in RT than RP Equivalent Greater in RT (short-term) 
Equivalent (long-term) 
 
Notes: EBRT = external beam radiotherapy; brachy = brachytherapy; ADT = androgen deprivation therapy; RP = radical 
prostatectomy; RT = radiotherapy; yrs = years. 
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Table 3. A comparison of key outcomes following radical prostatectomy and radiotherapy in the treatment of localized prostate 
cancer, stratified by evidentiary study design. 
 
Outcome 
Randomized controlled trials Observational cohort studies 
Evidence Caveats Evidence Caveats 
 
 
 
Survival 
No difference Underpowered 
and over-
representation of 
low-risk patients. 
Significantly improved overall and 
prostate cancer-specific survival for 
patients treated with surgery 
Residual confounding, 
with study design 
unable to fully account 
for baseline differences. 
Global HRQoL No difference n/a No difference Residual confounding 
Urinary function Conflicting evidence: 
likely no long-term 
differences 
n/a Greater incontinence early after 
surgery and greater urinary bother 
after radiotherapy. No differences 
long-term. 
Residual confounding 
Erectile function Conflicting evidence: 
likely no long-term 
differences 
n/a Worse erectile function early after 
surgery. No difference long-term. 
Residual confounding 
Bowel function Worse after 
radiotherapy 
n/a Worse bowel function early after 
radiotherapy. No difference long-term. 
Residual confounding 
Other 
complications 
No data Increased risk of urologic and rectal-
anal procedures, major surgeries, and 
hospitalizations to manage treatment-
related effects after radiotherapy. 
Residual confounding 
Secondary 
malignancies 
No data Increased risk of bladder, rectal and 
colorectal cancer after radiotherapy. 
Despite significant 
relative risk, small 
absolute risk. Residual 
confounding 
Note: HRQoL = health-related quality of life. 
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